Medtronic Cardiac Lead Nabs Expanded Labeling

The SelectSecure Model 3830 lead is now approved for pacing and sensing at the bundle of His or in the left bunch branch area.

Katie Hobbins, Managing Editor

October 17, 2022

2 Min Read
medtroniclogo3 (1).jpg
Image courtesy of Kristoffer Tripplaar / Alamy Stock Photo

Medtronic recently announced the FDA approval for expanded labeling of the SelectSecure MRI SureScan Model 3830 cardiac lead which taps into the hearts natural electrical system, giving patients needed therapy while avoiding potential complications sometimes seen with traditional pacing methods, like cardiomyopathy. This approach, commonly known as conduction system pacing, helps ensure that pacing closely mimics the hearts physiologic contractions, making sure the hearts ventricles are working in coordination.

"Conduction system pacing is more like simulating natural activation and can yield positive outcomes for patients," said Pugazhendhi Vijayaraman, MD, FHRS, director of electrophysiology at Geisinger Heart Institute in Wilkes-Barre, PA. "This approval signals to physicians that the Model 3830 lead is safe and effective for patients for conduction system pacing, and it may encourage more physicians to learn the procedure."

Originally approved in the United States for pacing and sensing in the atrium or right ventricle, the SelectSecure Model 3830 – a MR-conditional, steroid-eluting, bipolar lead – has more than 20 of proven performance and reliability, according to Medtronic. Now the cardia lead is approved for pacing and sensing at the bundle of His or in the left bunch branch area as an “alternative to apical pacing in the right ventricle in a single- or dual-chamber pacing system.” The lead received FDA approval for this indication based on real-world evidence showing high procedure success rates (92%) and low complication rates (2.5%).

The SelectSecure Model 3830 lead is now the first and only cardiac lead approved for conduction system pacing.

"Physicians are telling us about their excitement for the future of pacemakers, which will rely on conduction system and leadless pacing," said Robert C. Kowal, MD, PhD, general manager of cardiac pacing therapies at Medtronic. "Expanded labeling of this lead allows us to train physicians to successfully perform left bundle procedures, bringing the benefits of conduction system pacing to more patients."

About the Author(s)

Katie Hobbins

Managing Editor, MD+DI

Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like